Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Health Catalyst, Inc.NASDAQ: HCAT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $12.12M fell 1.7% year over year, behind the +18.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.
Context
- Depreciation & amortization amounted to 16.2% of revenue in FY2025, up 2.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -1.7% toward the trailing-twelve-month pace of +18.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 50.5M USD
- Year-over-year change
- +21.9%
- 4-year CAGR
- +7.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.5M | +21.9% |
| FY2024 | 2024-12-31 | 41.43M | -1.9% |
| FY2023 | 2023-12-31 | 42.22M | -12.6% |
| FY2022 | 2022-12-31 | 48.3M | +28.7% |
| FY2021 | 2021-12-31 | 37.53M | — |
Depreciation & Amortization vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 depreciation & amortization of $50.3M is the largest of the 11 companies compared; the peer median is $2.93M.
- Its year-over-year change of +18.5% is the 6th highest of 11, against a peer median of +30.9%.
- Depreciation & amortization amounts to 16.6% of revenue for HCAT, versus a peer median of 8.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.3M | +18.5% | +1.5% | 16.6% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $7.81M | -13.0% | +11.0% | 3469.8% | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.74M | +63.9% | -5.7% | 2.3% | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $672K | +1192.3% | +30.5% | 7.0% | |
| LTM Mar 2026 | $334K | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $103K | -90.0% | +10.5% | 0.2% | |
| Peer median (excluding HCAT) | $2.93M | +30.9% | +10.7% | 8.2% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Depreciation & Amortization | 37.53M | 48.3M | 42.22M | 41.43M | 50.5M |
| Deferred Income Tax | (7.13M) | (4.52M) | 8K | 77K | 81K |
| Stock-Based Compensation | 65.15M | 72.1M | 55.76M | 40.13M | 27.01M |
| Change in Working Capital | 4.62M | (13.91M) | (13.67M) | (660K) | (15.11M) |
| Accounts Receivables | 102K | 788K | (13.66M) | 4.28M | (1.81M) |
| Inventory | (8.33M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.2M | (4.7M) | 4.87M | 5.58M | (11.51M) |
| Other Working Capital | 7.64M | (9.99M) | (4.88M) | (10.52M) | (1.79M) |
| Other Non-Cash Items | 29.93M | 162K | 750K | 3.09M | 116.22M |
| Operating Cash Flow | (23.12M) | (35.27M) | (33.08M) | 14.56M | 731K |
| Capital Expenditures | (18.47M) | (17.41M) | (14.31M) | (16.4M) | (968K) |
| Acquisitions (Net) | (46.76M) | (27.85M) | (11.39M) | (80.28M) | (41.11M) |
| Purchases of Investments | (261.36M) | (308.96M) | (290.84M) | (168.31M) | (65.13M) |
| Sales of Investments | 186.89M | 315.17M | 336.8M | 242.07M | 163.95M |
| Other Investing Activities | 22K | (15.22M) | (13.04M) | (14.77M) | (20.54M) |
| Investing Cash Flow | (139.68M) | (39.02M) | 20.29M | (22.9M) | 36.19M |
| Debt Repayment | 0 | 0 | 0 | 151.32M | (232.29M) |
| Common Stock Issued | 245.18M | 0 | 0 | 2.58M | 1.51M |
| Common Stock Repurchased | 0 | (8.39M) | (1.81M) | 0 | (5M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 18.9M | 5.78M | 4.54M | (2.15M) | 0 |
| Financing Cash Flow | 264.08M | (2.61M) | 2.73M | 151.75M | (235.78M) |
| Effect of Forex Changes | (10K) | (11K) | 21K | (34K) | 27K |
| Net Change in Cash | 101.27M | (76.92M) | (10.04M) | 143.37M | (198.83M) |
| Free Cash Flow | (41.59M) | (52.68M) | (47.39M) | (1.84M) | (237K) |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.